Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer.
作者信息
Parker William B
机构信息
Southern Research Institute, 2000 Ninth Avenue, South Birmingham, Alabama 35205, USA.
出版信息
Chem Rev. 2009 Jul;109(7):2880-93. doi: 10.1021/cr900028p.
Abstract
摘要
相似文献
1
Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer.
Chem Rev. 2009 Jul;109(7):2880-93. doi: 10.1021/cr900028p.
2
[The biochemistry of the cancer cell. Purine and pyrimidine metabolism].
Padiatr Padol. 1986;21(4):323-34.
3
Improvement of purine and pyrimidine antimetabolite-based anticancer treatment by selective suppression of mycoplasma-encoded catabolic enzymes.
Lancet Oncol. 2009 Jun;10(6):628-35. doi: 10.1016/S1470-2045(09)70037-3.
4
Novel developments in metabolic disorders of purine and pyrimidine metabolism and therapeutic applications of their analogs.
Nucleosides Nucleotides Nucleic Acids. 2014;33(4-6):165-73. doi: 10.1080/15257770.2014.898071.
5
[Pyrimidine- and purine-type antimetabolites].
Cas Lek Cesk. 1972 Nov 3;111(45):1060-1.
6
Properties of purine and pyrimidine analogs.
Adv Enzyme Regul. 1991;31:433-43. doi: 10.1016/0065-2571(91)90028-k.
7
The design of cancer chemotherapy: metabolic modulation and cellular de novo versus salvage metabolism.
Antibiot Chemother (1971). 1980;28:86-93.
8
Modified pyrimidines specifically bind the purine riboswitch.
J Am Chem Soc. 2006 Nov 8;128(44):14214-5. doi: 10.1021/ja063645t.
9
Purine and pyrimidine metabolism: a firm basis for a transformed society.
Nucleosides Nucleotides Nucleic Acids. 2006;25(9-11):971-4. doi: 10.1080/15257770600887166.
10
Recent updates on purine and pyrimidine metabolism in physiological and pathological settings.
Nucleosides Nucleotides Nucleic Acids. 2020;39(10-12):1273-1280. doi: 10.1080/15257770.2020.1730891. Epub 2020 Mar 17.
引用本文的文献
1
Novel purine-linked 1,2,3-triazole derivatives as effective anticancer agents: design, synthesis, docking, DFT, and ADME-T investigations.
Sci Rep. 2025 Jul 23;15(1):26853. doi: 10.1038/s41598-025-95669-5.
2
Hybrid Molecules with Purine and Pyrimidine Derivatives for Antitumor Therapy: News, Perspectives, and Future Directions.
Molecules. 2025 Jun 23;30(13):2707. doi: 10.3390/molecules30132707.
3
From molecule to medicine: introducing emerging strategies to synthesize potent anticancer purine scaffolds.
RSC Adv. 2025 Jun 25;15(27):21604-21638. doi: 10.1039/d5ra02893k. eCollection 2025 Jun 23.
4
Synthesis of Purine-1,4,7,10-Tetraazacyclododecane Conjugate and Its Complexation Modes with Copper(II).
Molecules. 2025 Apr 4;30(7):1612. doi: 10.3390/molecules30071612.
5
Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy.
Discov Oncol. 2025 Apr 24;16(1):607. doi: 10.1007/s12672-025-02198-8.
6
Glucose- and glutamine-driven de novo nucleotide synthesis facilitates WSSV replication in shrimp.
Cell Commun Signal. 2025 Apr 22;23(1):191. doi: 10.1186/s12964-025-02186-z.
7
Nucleotide metabolism-associated drug resistance gene NDUFA4L2 promotes colon cancer progression and 5-FU resistance.
Sci Rep. 2025 Jan 2;15(1):570. doi: 10.1038/s41598-024-84353-9.
8
Systemic inhibition of purine biosynthesis prevents weight gain and improves metabolic health by increasing thermogenesis and decreasing food intake.
bioRxiv. 2024 Nov 1:2024.10.28.620705. doi: 10.1101/2024.10.28.620705.
9
Precious Cargo: The Role of Polymeric Nanoparticles in the Delivery of Covalent Drugs.
Molecules. 2024 Oct 19;29(20):4949. doi: 10.3390/molecules29204949.
10
Azole Combinations and Multi-Targeting Drugs That Synergistically Inhibit .
J Fungi (Basel). 2024 Oct 7;10(10):698. doi: 10.3390/jof10100698.
本文引用的文献
1
p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
Cancer Res. 2008 Nov 15;68(22):9358-66. doi: 10.1158/0008-5472.CAN-08-1860.
2
Prodrug cancer gene therapy.
Cancer Lett. 2008 Nov 8;270(2):191-201. doi: 10.1016/j.canlet.2008.04.023. Epub 2008 May 27.
3
Repair of 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine-induced DNA single-strand breaks by transcription-coupled nucleotide excision repair.
Cancer Res. 2008 May 15;68(10):3881-9. doi: 10.1158/0008-5472.CAN-07-6885.
4
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
Int J Cancer. 2008 Jul 1;123(1):8-13. doi: 10.1002/ijc.23607.
5
Pharmacology and mechanism of action of forodesine, a T-cell targeted agent.
Semin Oncol. 2007 Dec;34(6 Suppl 5):S8-12. doi: 10.1053/j.seminoncol.2007.11.003.
6
Forodesine treatment and post-transplant graft-versus-host disease in two patients with acute leukemia: facilitation of graft-versus-leukemia effect?
Semin Oncol. 2007 Dec;34(6 Suppl 5):S35-9. doi: 10.1053/j.seminoncol.2007.11.005.
7
Purine nucleoside phosphorylase inhibition as a novel therapeutic approach for B-cell lymphoid malignancies.
Semin Oncol. 2007 Dec;34(6 Suppl 5):S29-34. doi: 10.1053/j.seminoncol.2007.11.004.
8
Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine.
Semin Oncol. 2007 Dec;34(6 Suppl 5):S13-20. doi: 10.1053/j.seminoncol.2007.11.002.
9
Nelarabine: a novel purine antimetabolite antineoplastic agent.
Clin Ther. 2007 Sep;29(9):1887-99. doi: 10.1016/j.clinthera.2007.09.002.
10
Troxacitabine in acute leukemia.
Hematology. 2007 Jun;12(3):219-27. doi: 10.1080/10245330701406881.
Zotero 插件